Joanne Blum, MD, PhD, oncologist, Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discusses the EMBRACA trial.

The trial is a phase III, open-label, randomized, parallel, two-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in patients with 

-mutated metastatic breast cancer. The trial aims to include about 429 patients, says Blum, but it is event-driven so it is possible there might be fewer.

The patients included in this trial are rare, says Blum. Patients with a 

 mutation amount to approximately 7% of the general breast cancer population and only a few of them develop metastatic disease. To identify enough patients for this trial takes a worldwide effort, says Blum. There are plans to expand it even further to more countries and sites in the near future.

View more from the 2015 San Antonio Breast Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

San Antonio Breast Cancer Symposium

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.

Dr. Joanne Blum on the EMBRACA Trial in Metastatic BRCA-Mutant Breast Cancer